Holen Sie sich die Stockscreener-App
30.14
3.57%
1.04
Handel nachbörslich:
30.05
-0.09
-0.30%
Schlusskurs vom Vortag:
$29.10
Offen:
$29.26
24-Stunden-Volumen:
532.57K
Relative Volume:
3.41
Marktkapitalisierung:
$498.45M
Einnahmen:
$3.25M
Nettoeinkommen (Verlust:
$-116.80M
KGV:
-9.882
EPS:
-3.05
Netto-Cashflow:
$-98.17M
1W Leistung:
+14.25%
1M Leistung:
+166.73%
6M Leistung:
+239.41%
1J Leistung:
+89.32%
1-Tages-Spanne:
$28.07
$31.76
1-Wochen-Bereich:
$24.34
$31.76
52-Wochen-Spanne:
$5.6652
$31.76
Rapt Therapeutics Inc Stock (RAPT) Company Profile
Firmenname
Rapt Therapeutics Inc
Sektor
Branche
Telefon
(650) 489-9000
Adresse
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Vergleichen Sie RAPT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RAPT
Rapt Therapeutics Inc
|
30.14 | 481.25M | 3.25M | -116.80M | -98.17M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
403.30 | 104.83B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
600.00 | 63.59B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.35 | 60.43B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
800.00 | 48.45B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
343.87 | 37.91B | 4.56B | -176.77M | 225.30M | -1.7177 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-26 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-07-30 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2025-05-22 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-12-26 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-11-13 | Herabstufung | Stifel | Buy → Hold |
| 2024-11-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-11-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-05-14 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-05-10 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-05-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-02-22 | Herabstufung | UBS | Buy → Neutral |
| 2024-02-21 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-02-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-02-21 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-02-20 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-02-16 | Eingeleitet | Evercore ISI | Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-09-14 | Eingeleitet | Berenberg | Buy |
| 2023-08-09 | Eingeleitet | Stifel | Buy |
| 2023-06-15 | Eingeleitet | Barclays | Overweight |
| 2023-01-04 | Eingeleitet | Guggenheim | Buy |
| 2022-12-01 | Eingeleitet | Goldman | Buy |
| 2022-09-21 | Eingeleitet | CapitalOne | Overweight |
| 2022-05-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-12-09 | Eingeleitet | JP Morgan | Overweight |
| 2021-08-12 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-21 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-04-13 | Eingeleitet | ROTH Capital | Buy |
| 2019-11-25 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-11-25 | Eingeleitet | UBS | Buy |
| 2019-11-25 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Rapt Therapeutics Inc Aktie (RAPT) Neueste Nachrichten
Why RAPT Therapeutics Inc. stock is seen as undervaluedQuarterly Investment Review & Free Reliable Trade Execution Plans - newser.com
How analysts rate RAPT Therapeutics Inc. stock today2025 Investor Takeaways & Risk Managed Trade Strategies - newser.com
Why RAPT Therapeutics Inc. (0RA0) stock stays on top picksWeekly Gains Report & Free Daily Entry Point Trade Alerts - newser.com
Is RAPT Therapeutics Inc. (0RA) stock bottoming after sell offQuarterly Profit Summary & High Conviction Buy Zone Picks - newser.com
How RAPT Therapeutics Inc. (0RA) stock performs in volatility spikesJuly 2025 Big Picture & Real-Time Chart Breakout Alerts - newser.com
Will RAPT Therapeutics Inc. stock maintain growth story2025 Technical Patterns & Reliable Price Action Trade Plans - newser.com
Can swing trading help recover from RAPT Therapeutics Inc. lossesJuly 2025 Fed Impact & Community Consensus Picks - newser.com
How to use a screener to detect RAPT Therapeutics Inc. breakoutsFed Meeting & Comprehensive Market Scan Reports - newser.com
Published on: 2025-10-02 21:38:33 - newser.com
Will RAPT Therapeutics Inc. (0RA) stock draw ESG focused fundsRisk Management & Daily Profit Focused Screening - newser.com
Clear Street Maintains RAPT Therapeutics (RAPT) Buy Recommendation - Nasdaq
Published on: 2025-09-30 02:47:57 - newser.com
Rapt Therapeutics stock price target raised to $41 from $24 at Clear Street - Investing.com Canada
What hedge fund moves indicate for RAPT Therapeutics Inc. (0RA) stockJuly 2025 Macro Moves & Weekly Consistent Profit Watchlists - newser.com
RAPT Therapeutics stock rises after FDA clears IND for food allergy trial By Investing.com - Investing.com Nigeria
RAPT Therapeutics stock rises after FDA clears IND for food allergy trial - Investing.com Nigeria
RAPT Therapeutics Announces FDA Clearance of IND - GlobeNewswire
Rapt Therapeutics announces FDA clearance to proceed to phase 2b trial of RPT904 in food allergy - MarketScreener
RAPT Therapeutics' Food Allergy Drug Gets FDA Clearance for Phase 2b Trial - MarketScreener
RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy - The Manila Times
RAPT Therapeutics Announces FDA Clearance for IND Application to Initiate Phase 2b Trial of RPT904 in Food Allergy Treatment - Quiver Quantitative
How to build a dashboard for RAPT Therapeutics Inc. stockJuly 2025 Sector Moves & AI Driven Stock Movement Reports - newser.com
FDA Green Light: RAPT Therapeutics' Novel Food Allergy Treatment Heads to Critical Phase 2b Trial - Stock Titan
Finanzdaten der Rapt Therapeutics Inc-Aktie (RAPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.68%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):